Laure-Hélène Ouisse, Séverine Remy, Aude Lafoux, Thibaut Larcher, Laurent Tesson, Vanessa Chenouard, Carole Guillonneau, Lucas Brusselle, Nadège Vimond, Karl Rouger, Yann Péréon, Alexis Chenouard, Christèle Gras-Le Guen, Cécile Braudeau, Régis Josien, Corinne Huchet, Ignacio Anegon
Corticosteroids (CS) are standard therapy for the treatment of Duchenne's muscular dystrophy (DMD). Even though they decrease inflammation, they have limited efficacy and are associated with significant side effects. There is therefore the need for new protolerogenic treatments to replace CS. Dystrophin-deficient rats ( Dmd mdx ) closely resemble the pathological phenotype of DMD patients. We performed the first Immunophenotyping of Dmd mdx rats and showed leukocyte infiltration in skeletal and cardiac muscles, which consisted mostly of macrophages and T cells including CD45RChigh T cells...
2019: Frontiers in Immunology